What is Castle Biosciences's SG&A?

Castle Biosciences (CSTL) reported SG&A of $64.9M in Q1 2026.

How has Castle Biosciences's SG&A changed year-over-year?

Castle Biosciences's SG&A increased by 10.7% year-over-year, from $58.62M to $64.9M.

What is the long-term trend for Castle Biosciences's SG&A?

Over 4 years (2021 to 2025), Castle Biosciences's SG&A has grown at a 27.5% compound annual growth rate (CAGR), from $86.74M to $229.32M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Castle Biosciences CSTL SG&A

SG&A at other companies

Labcorp HoldingsLH

$551M+0.9%

Personalis, Inc.PSNL

$17.9M+46.0%

GeneDx HoldingsWGS

$74.59M+47.9%

BillionToOne, Inc. BLLN

$46.57M+56.0%

Tempus AI, Inc.TEM

$212.59M+37.5%

TEC

Bio-TechneTECH

$109.34M-27.7%

Other financials

Income statement

See full

Revenue$83.7M-4.9%

Gross profit$63.1M-11.8%

Operating income-$18.4M+34.1%

Net income-$14.5M+43.8%

EPS (diluted)-$0.49+45.6%

Balance sheet

See full

Cash & equivalents$63.8M-28.9%

Total debt$36.7M+42.1%

Total equity$461.4M+4.8%

Total assets$547.8M+9.2%

Cash flow

See full

Operating cash flow-$22.1M-267%

CapEx$12.5M+163%

Free cash flow-$34.6M-221%

Valuation

See full

Market cap$694.86M+29.9%

Enterprise value$667.82M+41.8%

P/S2×+0.5×

Profitability

See full

Gross margin77.9%-4.1pp

Operating margin-9.8%-30.8pp

Net margin-3.8%-10.2pp

FCF margin1.3%-10.7pp

Returns & leverage

See full

Return on equity-2.8%-10.6pp

Debt / equity0.1×0.0×

Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Castle Biosciences's SG&A?: Castle Biosciences (CSTL) reported SG&A of $64.9M in Q1 2026.
How has Castle Biosciences's SG&A changed year-over-year?: Castle Biosciences's SG&A increased by 10.7% year-over-year, from $58.62M to $64.9M.
What is the long-term trend for Castle Biosciences's SG&A?: Over 4 years (2021 to 2025), Castle Biosciences's SG&A has grown at a 27.5% compound annual growth rate (CAGR), from $86.74M to $229.32M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.